Takeda Pharmaceutical Current Valuation vs. Return On Asset
| TKD Stock | EUR 25.01 0.12 0.48% |
For Takeda Pharmaceutical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Takeda Pharmaceutical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Takeda Pharmaceutical utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Takeda Pharmaceutical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Takeda Pharmaceutical over time as well as its relative position and ranking within its peers.
Takeda |
Takeda Pharmaceutical Return On Asset vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Takeda Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Takeda Pharmaceutical value to that of its competitors to determine the firm's financial worth. Takeda Pharmaceutical is currently regarded number one company in current valuation category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The ratio of Current Valuation to Return On Asset for Takeda Pharmaceutical is about 2,881,164,200,648 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Takeda Pharmaceutical's earnings, one of the primary drivers of an investment's value.Takeda Current Valuation vs. Competition
Takeda Pharmaceutical is currently regarded number one company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Drug Manufacturers - Specialty & Generic industry is at this time estimated at about 169.74 Billion. Takeda Pharmaceutical totals roughly 71.16 Billion in current valuation claiming about 42% of equities under Drug Manufacturers - Specialty & Generic industry.
Takeda Return On Asset vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Takeda Pharmaceutical |
| = | 71.16 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Takeda Pharmaceutical |
| = | 0.0247 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Takeda Return On Asset Comparison
Takeda Pharmaceutical is currently under evaluation in return on asset category among its peers.
Takeda Pharmaceutical Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Takeda Pharmaceutical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Takeda Pharmaceutical will eventually generate negative long term returns. The profitability progress is the general direction of Takeda Pharmaceutical's change in net profit over the period of time. It can combine multiple indicators of Takeda Pharmaceutical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. Takeda Pharmaceutical operates under Drug Manufacturers - Specialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 49578 people.
Takeda Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Takeda Pharmaceutical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Takeda Pharmaceutical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Takeda Pharmaceutical's important profitability drivers and their relationship over time.
Use Takeda Pharmaceutical in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Takeda Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Takeda Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Takeda Pharmaceutical Pair Trading
Takeda Pharmaceutical Pair Trading Analysis
The ability to find closely correlated positions to Takeda Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Takeda Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Takeda Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Takeda Pharmaceutical to buy it.
The correlation of Takeda Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Takeda Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Takeda Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Takeda Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Takeda Pharmaceutical position
In addition to having Takeda Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Materials ETFs Thematic Idea Now
Materials ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Materials ETFs theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Materials ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Takeda Stock
To fully project Takeda Pharmaceutical's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Takeda Pharmaceutical at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Takeda Pharmaceutical's income statement, its balance sheet, and the statement of cash flows.